TNSN05172A1 - ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - Google Patents
ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONInfo
- Publication number
- TNSN05172A1 TNSN05172A1 TNP2005000172A TNSN05172A TNSN05172A1 TN SN05172 A1 TNSN05172 A1 TN SN05172A1 TN P2005000172 A TNP2005000172 A TN P2005000172A TN SN05172 A TNSN05172 A TN SN05172A TN SN05172 A1 TNSN05172 A1 TN SN05172A1
- Authority
- TN
- Tunisia
- Prior art keywords
- cycloalkyl
- alkyl
- group
- alkylene
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Abstract
Composé répondant à la formule générale (I) dans laquelle n représente un nombre entier allant de 1 à 7 ; A est choisi parmi un ou plusieurs groupes X, Y et/ou Z ; X représente un groupe C1-2-alkylène éventuellement substitué par un ou plusieurs groupes C1-12-alkyle, C3-7cycloalkyle ou C3-7-cycloalkyl-C1-6-alkylène; Y représente un groupe C2-alcènylène éventuellement substitué par un ou plusieurs groupes C1-12 alkyle, C3-7-cycloalkyle ou C3-7-cycloalkyl-C1-6-alkylène; Z représente un groupe C3-7-cycloalkyle, de formule, m représente un nombre entier allant de 1 à 5 ; p et q représentent des nombres entiers et sont définis tels que p+q soit un nombre allant de 1 à 5 ; R1 représente un atome d'hydrogène, d'halogène ou un groupe hydroxyle, cyano, nitro, C1-4-alkyle, C1-4-alcoxy,C1-4-thioalkyle, C1-4-fluoroalkyle, C1-4-fluoroalcoxy, C1-4-fluorothioalkyle ; R2 représente un atome d'hydrogène, d'halogène, ou un groupe cyano, nitro, hydroxyle, C1-4-alkyle, C1-4-alcoxy, C1-4-thioalkyle, C1-4-fluoroalkyle, C1-4-fluoroalcoxy, C1-4-fluorothioalkyle, ou un groupe de type aryle ou hétéroaryle éventuellement substitué par un ou plusieurs substituants; R3 représente un groupe de formule générale CHR4CONHR5 dans laquelle R4 représente un atome d'hydrogène ou un groupe Cl- 3-alkyle et R5 représente un atome d'hydrogène ou un groupe C1-3-alkyle, C3-5-cycloalkyle, C3-7-cycloalkyle-C1-6-alkylène; à l'état de base, de sel d'addition à un acide, d'hydrate ou de solvat. Application en thérapeutique.A compound of the general formula (I) wherein n is an integer from 1 to 7; A is selected from one or more X, Y and / or Z groups; X represents a C1-2-alkylene group optionally substituted with one or more C1-12-alkyl, C3-7cycloalkyl or C3-7-cycloalkyl-C1-6-alkylene groups; Y represents a C2-alkenylene group optionally substituted by one or more C1-12 alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-6-alkylene groups; Z represents a C3-7-cycloalkyl group of formula, m represents an integer ranging from 1 to 5; p and q represent integers and are defined such that p + q is a number ranging from 1 to 5; R1 represents a hydrogen, halogen atom or a hydroxyl, cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-4-fluoroalkyl, C1-4-fluoroalkoxy group, C1-4-fluorothioalkyl; R2 represents a hydrogen, halogen atom, or a cyano, nitro, hydroxyl, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-4-fluoroalkyl, C1-4-fluoroalkoxy group; C1-4-fluorothioalkyl, or an aryl or heteroaryl group optionally substituted with one or more substituents; R3 represents a group of the general formula CHR4CONHR5 in which R4 represents a hydrogen atom or a Cl-3-alkyl group and R5 represents a hydrogen atom or a C1-3-alkyl, C3-5-cycloalkyl, C3- 7-cycloalkyl-C1-6-alkylene; in the form of a base, an acid addition salt, a hydrate or a solvate. Application in therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0300704A FR2850377B1 (en) | 2003-01-23 | 2003-01-23 | ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
PCT/FR2004/000139 WO2004067498A2 (en) | 2003-01-23 | 2004-01-22 | Aryl alkyl carbamate derivatives production and use thereof in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN05172A1 true TNSN05172A1 (en) | 2007-05-14 |
Family
ID=32669151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2005000172A TNSN05172A1 (en) | 2003-01-23 | 2005-06-30 | ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
Country Status (34)
Country | Link |
---|---|
US (1) | US7632850B2 (en) |
EP (1) | EP1590321B1 (en) |
JP (1) | JP4617292B2 (en) |
KR (1) | KR20050104352A (en) |
CN (2) | CN101058564B (en) |
AR (1) | AR042746A1 (en) |
AT (1) | ATE465990T1 (en) |
AU (1) | AU2004207657B2 (en) |
BR (1) | BRPI0406901A (en) |
CA (1) | CA2511941A1 (en) |
CY (1) | CY1110216T1 (en) |
DE (1) | DE602004026826D1 (en) |
DK (1) | DK1590321T3 (en) |
EA (1) | EA008801B1 (en) |
ES (1) | ES2344454T3 (en) |
FR (1) | FR2850377B1 (en) |
HK (1) | HK1085193A1 (en) |
HR (1) | HRP20050631A2 (en) |
IL (1) | IL169444A (en) |
IS (1) | IS7916A (en) |
MA (1) | MA27609A1 (en) |
ME (1) | MEP21308A (en) |
MX (1) | MXPA05007848A (en) |
NO (1) | NO20053593L (en) |
NZ (1) | NZ541148A (en) |
PL (1) | PL378022A1 (en) |
PT (1) | PT1590321E (en) |
RS (1) | RS20050562A (en) |
SI (1) | SI1590321T1 (en) |
TN (1) | TNSN05172A1 (en) |
TW (1) | TWI330628B (en) |
UA (1) | UA86013C2 (en) |
WO (1) | WO2004067498A2 (en) |
ZA (1) | ZA200505351B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2864080B1 (en) * | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | 1-PIPERAZINE-AND-1-HOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2865205B1 (en) | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | ARYLOXYALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
FR2866884B1 (en) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | ARYL-AND HETEROARYL-PIPERIDINECARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2866885B1 (en) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | PIPERIDINYLALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
FR2866886B1 (en) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | ARYL-AND HETEROARYL-AKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
DE102004039326A1 (en) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Treatment of neurodegenerative diseases, specifically Alzheimer's disease and Down syndrome, uses a chemical/biological substance which inhibits fatty acid amide hydrolase without inhibiting cyclooxygenase-1 and/or 2 |
MX2007008134A (en) * | 2004-12-30 | 2008-01-16 | Johnson & Johnson | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase. |
US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
US20090099240A1 (en) * | 2006-10-02 | 2009-04-16 | N.V. Organon | Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
EP2096915A1 (en) * | 2006-11-20 | 2009-09-09 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
US8124605B2 (en) * | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
TW200948805A (en) * | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
CN101537006B (en) * | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | Application of pyridazinone compounds in preparing antitumor drugs |
UA108233C2 (en) | 2010-05-03 | 2015-04-10 | Fatty acid amide hydrolysis activity modulators | |
RU2583435C2 (en) * | 2010-07-28 | 2016-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Peripherally restricted faah inhibitors |
MX354772B (en) | 2011-08-19 | 2018-03-21 | Univ California | Meta-substituted biphenyl peripherally restricted faah inhibitors. |
US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
BR112021007830A2 (en) * | 2018-11-20 | 2021-08-03 | Bayer Aktiengesellschaft | subtype c (al-fa-2c) adrenoceptor-alpha2 antagonists for the treatment of sleep apnea |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
IT649883A (en) * | 1960-05-24 | |||
US3742022A (en) * | 1967-05-08 | 1973-06-26 | A Verbiscar | Carbamate esters of physiologically active ph enenthylamines |
DE3003653A1 (en) * | 1980-02-01 | 1981-08-06 | Hoechst Ag, 6000 Frankfurt | N-substd. oxazolidine-2,4-di:one derivs. prodn. - by one-pot reaction of alkali cyanate with organic halide and alpha-hydroxy carboxylic acid ester |
JP2616989B2 (en) * | 1989-04-03 | 1997-06-04 | 株式会社トクヤマ | 2,4-oxazolidinedione compound |
EP0545478A1 (en) * | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclic compounds as tachykinin antagonists |
GB9210744D0 (en) * | 1992-05-20 | 1992-07-08 | Pfizer Ltd | Antiviral peptides |
US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
MXPA03009850A (en) * | 2001-04-27 | 2004-02-12 | Bristol Myers Squibb Co | Bisarylimidazolyl fatty acid amide hydrolase inhibitors. |
WO2003065989A2 (en) * | 2002-02-08 | 2003-08-14 | Bristol-Myers Squibb Company | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
-
2003
- 2003-01-23 FR FR0300704A patent/FR2850377B1/en not_active Expired - Fee Related
-
2004
- 2004-01-20 TW TW093101679A patent/TWI330628B/en not_active IP Right Cessation
- 2004-01-22 EA EA200500979A patent/EA008801B1/en not_active IP Right Cessation
- 2004-01-22 AR ARP040100170A patent/AR042746A1/en unknown
- 2004-01-22 MX MXPA05007848A patent/MXPA05007848A/en active IP Right Grant
- 2004-01-22 KR KR1020057013551A patent/KR20050104352A/en active IP Right Grant
- 2004-01-22 CA CA002511941A patent/CA2511941A1/en not_active Abandoned
- 2004-01-22 NZ NZ541148A patent/NZ541148A/en not_active IP Right Cessation
- 2004-01-22 DE DE602004026826T patent/DE602004026826D1/en not_active Expired - Lifetime
- 2004-01-22 PT PT04704251T patent/PT1590321E/en unknown
- 2004-01-22 JP JP2006502114A patent/JP4617292B2/en not_active Expired - Fee Related
- 2004-01-22 AU AU2004207657A patent/AU2004207657B2/en not_active Ceased
- 2004-01-22 SI SI200431464T patent/SI1590321T1/en unknown
- 2004-01-22 RS YUP-2005/0562A patent/RS20050562A/en unknown
- 2004-01-22 UA UAA200508210A patent/UA86013C2/en unknown
- 2004-01-22 EP EP04704251A patent/EP1590321B1/en not_active Expired - Lifetime
- 2004-01-22 DK DK04704251.0T patent/DK1590321T3/en active
- 2004-01-22 PL PL378022A patent/PL378022A1/en not_active Application Discontinuation
- 2004-01-22 CN CN2007100840856A patent/CN101058564B/en not_active Expired - Fee Related
- 2004-01-22 WO PCT/FR2004/000139 patent/WO2004067498A2/en active Application Filing
- 2004-01-22 CN CNB2004800027704A patent/CN100506788C/en not_active Expired - Fee Related
- 2004-01-22 ZA ZA200505351A patent/ZA200505351B/en unknown
- 2004-01-22 ES ES04704251T patent/ES2344454T3/en not_active Expired - Lifetime
- 2004-01-22 BR BR0406901-3A patent/BRPI0406901A/en not_active IP Right Cessation
- 2004-01-22 AT AT04704251T patent/ATE465990T1/en active
- 2004-01-22 ME MEP-213/08A patent/MEP21308A/en unknown
-
2005
- 2005-06-27 IS IS7916A patent/IS7916A/en unknown
- 2005-06-28 IL IL169444A patent/IL169444A/en not_active IP Right Cessation
- 2005-06-30 TN TNP2005000172A patent/TNSN05172A1/en unknown
- 2005-07-11 HR HR20050631A patent/HRP20050631A2/en not_active Application Discontinuation
- 2005-07-12 MA MA28384A patent/MA27609A1/en unknown
- 2005-07-21 US US11/186,242 patent/US7632850B2/en not_active Expired - Fee Related
- 2005-07-22 NO NO20053593A patent/NO20053593L/en not_active Application Discontinuation
-
2006
- 2006-05-02 HK HK06105197.4A patent/HK1085193A1/en not_active IP Right Cessation
-
2010
- 2010-07-20 CY CY20101100676T patent/CY1110216T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05172A1 (en) | ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
MA27390A1 (en) | DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
TNSN04208A1 (en) | N- [PHENYL (PIPERIDIN-2-YL) METHYL] BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
FR2854633A1 (en) | PIPERIDINYL-AND PIPERAZINYL-ALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
MA28234A1 (en) | 1-PIPERAZINE AND 1-HOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS INHIBITORS OF THE FAAH ENZYME | |
HUP0402310A2 (en) | 1,6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them | |
HUP0400247A2 (en) | Azaindoles, process for their preparation and pharmaceutical compositions containing them | |
MA28098A1 (en) | DERIVATIVES OF N- [PHENYL (PYRROLIDIN-2-YL) METHYL] BENZAMIDE AND N - [(AZEPAN-2-YL) PHENYLMETHYL] BENZAMIDE, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
HUP0203895A2 (en) | Substituted azaindoles and pharmaceutical compositions containing them and their use | |
RU2000125568A (en) | DERIVATIVES OF CYCLOALKENES, THEIR RECEPTION AND APPLICATION | |
EA200401614A1 (en) | O-Substituted Hydroxyaryl Derivatives | |
RU97105381A (en) | COMPOUNDS AND METHODS FOR CANCER TREATMENT | |
DK0669918T3 (en) | Furyl or thienylcarbonyl-substituted taxanes and pharmaceutical compositions containing them | |
HUP0301422A2 (en) | Pharmaceutical compositions of estrogenic agents | |
RU2005140570A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A HISTONDEACETYLASE INHIBITOR | |
RU2004106617A (en) | ANTITUMOR ANALOGUES | |
HUP0400246A2 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
TNSN07253A1 (en) | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS LIGANDS OF TRPV1 VANILLOID RECEPTOR | |
HUP0105073A2 (en) | 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them | |
MA31674B1 (en) | Derivatives of 7-alkynil-1,8-naviteredone prepared and therapeutic uses | |
FR2934994B1 (en) | DERIVATIVES OF 2-ALKYL-6CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZ-1,2-B! PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
HUP0201722A2 (en) | Pharmaceutical compositions for treating alcoholism and alcohol dependence | |
MA32019B1 (en) | Azetidine derivatives, their preparation and their application in therapeutics | |
HUP0402341A2 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
FR2854634A1 (en) | NOVEL THIADIAZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |